New pill tested to tame autoimmune dryness disease

This study tested whether a pill called baricitinib could help control the disease activity and ease symptoms in people with active primary Sjogren's syndrome, an autoimmune disorder that causes severe dryness and fatigue. About 87 adults with moderate disease activity were randomly assigned to take either the standard medication (hydroxychloroquine) or baricitinib, with or without the standard medication, for 24 weeks. The main goal was to see if the baricitinib group showed more improvement in standard disease and symptom scores after 12 weeks.